Milan Kovacevic
Profile
Milan Kovacevic worked as a Senior Medical Director & Medical Director at Synvista Therapeutics, Inc., a Medical Officer-Global Safety & Project Manager at Kendle International LLC, a Vice President-Clinical Operations at GenVec, Inc., and a Clinical Research Scientist at Cangene Corp.
He graduated from the University of Belgrade with a graduate degree and an MBA.
Former positions of Milan Kovacevic
Companies | Position | End |
---|---|---|
GENVEC INC | Chief Tech/Sci/R&D Officer | - |
Kendle International LLC
Kendle International LLC Miscellaneous Commercial ServicesCommercial Services Kendle International LLC provides research and development services to biopharmaceutical companies by offering value-added clinical research services and proprietary information technology. The company was founded in 1981 and is headquartered in Cincinnati, OH. | Corporate Officer/Principal | - |
CANGENE CORPORATION | Chief Tech/Sci/R&D Officer | - |
SYNVISTA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Training of Milan Kovacevic
University of Belgrade | Graduate Degree |
Experiences
Positions held
Linked companies
Listed companies | 1 |
---|---|
SYNVISTA THERAPEUTICS, INC. | Health Technology |
Private companies | 3 |
---|---|
Kendle International LLC
Kendle International LLC Miscellaneous Commercial ServicesCommercial Services Kendle International LLC provides research and development services to biopharmaceutical companies by offering value-added clinical research services and proprietary information technology. The company was founded in 1981 and is headquartered in Cincinnati, OH. | Commercial Services |
Cangene Corp.
Cangene Corp. Pharmaceuticals: MajorHealth Technology Cangene Corp. developed, manufactured and sold biopharmaceutical drugs. The company was founded on February 22, 1984 and was headquartered in Winnipeg, Canada. | Health Technology |
GenVec, Inc.
GenVec, Inc. Pharmaceuticals: MajorHealth Technology GenVec, Inc. operated as a clinical-stage gene delivery company, which engaged in the development of therapeutics and vaccines. The firm designs, tests, and manufactured adenoviral-based product candidates using its proprietary AdenoVerse platform. Its products included CGF166-Hearing Loss; GV2311-RSV Vaccine; and GV2207-HSV-2 Immunotherapeutic. The company was founded in December 1992 and was headquartered in Rockville, MD. | Health Technology |
- Stock Market
- Insiders
- Milan Kovacevic